(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of -39.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.51%.
Bicycle Therapeutics's revenue in 2026 is $61,205,000.On average, 13 Wall Street analysts forecast BCYC's revenue for 2026 to be $1,095,598,410, with the lowest BCYC revenue forecast at $183,171,343, and the highest BCYC revenue forecast at $2,729,441,998. On average, 13 Wall Street analysts forecast BCYC's revenue for 2027 to be $663,112,460, with the lowest BCYC revenue forecast at $0, and the highest BCYC revenue forecast at $2,594,285,764.
In 2028, BCYC is forecast to generate $1,114,636,471 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,497,041,962.